AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25316715
Drug: t:slim Insulin
RxNorm normalized name: t:slim Insulin Delivery System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: t:slim Insulin Pump
Trial: 25316715
Drug: Revel Insulin
RxNorm normalized name: Paradigm Revel Insulin Pump, Blue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Revel Insulin Pump
Trial: 19489765
Drug: Omega-3 supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 supplementation (1.6 g eicosapentaenoic acid and 1.1 g docosahexaenoic acid)
Trial: 16957638
Drug: Intravenous hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous hydrocortisone 300 mg daily for 3 days, tapered over 1 week
Trial: 16957638
Drug: Intravenous metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous metoclopramide 10 mg 3 times daily for 1 week
Trial: 9525336
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (850 mg/day)
Trial: 26310941
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (daily walking for 30 min)
Trial: 24250874
Drug: Carbamazepine (300-600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine (300-600 mg/day)
Trial: 24250874
Drug: Oxcarbazepine (450-900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxcarbazepine (450-900 mg/day)
Trial: 21353105
Drug: IV acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV acetaminophen 1000 mg q6h
Trial: 21353105
Drug: IV acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV acetaminophen 650 mg q4h
Trial: 21353105
Drug: IV placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV placebo 100 mL q6h
Trial: 21353105
Drug: IV placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV placebo 65 mL q4h
Trial: 19128627
Drug: Parental guide
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parental guide and treatment algorithm
Trial: 19128627
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care with acetaminophen (15 mg/kg) and morphine (0.3 mg/kg)
Trial: 30403954
Drug: Zoliflodacin 2
RxNorm normalized name: Zoliflodacin
DrugBank: Zoliflodacin (DB12817)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zoliflodacin 2 g
Trial: 30403954
Drug: Zoliflodacin 3
RxNorm normalized name: Zoliflodacin
DrugBank: Zoliflodacin (DB12817)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zoliflodacin 3 g
Trial: 20670400
Drug: HFE homozygous
RxNorm normalized name: HOMOZYGOUS YUCATAN MINIATURE PIG ATAXIA TELANGIECTASIA MUTATED (ATM) GENE DISRUPTED BY A ATM-NEO RDNA CONSTRUCT IN EXON 57
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFE homozygous or compound heterozygous carriers
Trial: 12554608
Drug: Cyanamide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyanamide (200 mg daily)
Trial: 8800992
Drug: Transdermal scopolamine
RxNorm normalized name: Transderm Scop
DrugBank: Scopolamine (DB00747)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal scopolamine (500 micrograms delivered over 72 h)
Trial: 1738571
Drug: Both agents
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both agents (AT and MT)
Trial: 30832590
Drug: CVS as
RxNorm normalized name: CVS Aspirin 325mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVS as a lightwand (CVS‐L)
Trial: 26354593
Drug: Music-with-movement intervention,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music-with-movement intervention, developed by a registered music therapist, taught to staff over five weekly 1.5 h sessions.
Trial: 22395920
Drug: Bovine intestinal
RxNorm normalized name: bovine intestinal mucosa preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine intestinal alkaline phosphatase (bIAP) administered as an intravenous bolus followed by continuous infusion for 36 hours.
Trial: 22395920
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered as an intravenous bolus followed by continuous infusion for 36 hours.
Trial: 18520981
Drug: Creatine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine (10 g/d)
Trial: 15942183
Drug: Sequential antiarrhythmic
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential antiarrhythmic therapy (propafenone, sotalol, disopyramide) followed by amiodarone if needed
Trial: 15942183
Drug: Amiodarone as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone as the third antiarrhythmic agent
Trial: 7791815
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (7.5 mg daily for two years)
Trial: 28557178
Drug: Antidepressants (imipramine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants (imipramine, venlafaxine, escitalopram)
Trial: 28557178
Drug: Anticonvulsants (pregabalin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticonvulsants (pregabalin, oxcarbazepine)
Trial: 14576100
Drug: Cefepime (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefepime (2 g three times a day)
Trial: 14576100
Drug: Imipenem-cilastatin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem-cilastatin (500 mg four times a day)
Trial: 8956393
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream for a minimum of 30 minutes
Trial: 8956393
Drug: Lidocaine infiltration
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine infiltration with 3 mL of 1% lidocaine
Trial: 4015742
Drug: suprofen (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suprofen (200 mg/ml) as i.v. bolus injections
Trial: 4015742
Drug: suprofen (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suprofen (200 mg/ml) as infusions
Trial: 4015742
Drug: suprofen (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suprofen (200 mg/ml) as i.v. bolus injections and infusions
Trial: 20134408
Drug: Olanzapine (OLZ)
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine (OLZ) 5 mg for 3 days then OLZ 10 mg for 12 days
Trial: 16410889
Drug: Full set
RxNorm normalized name: Silhouette Infusion Full Set-43 inch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full set of HBV vaccines
Trial: 11185684
Drug: Iodixanol-270 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodixanol-270 (20 ml)
Trial: 11185684
Drug: Iopentol-150 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iopentol-150 (20 ml)
Trial: 19590019
Drug: Active corticosteroid
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active corticosteroid inhaler (quadrupling the dose)
Trial: 19590019
Drug: Placebo inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo inhaler (no change in corticosteroid dose)
Trial: 11870117
Drug: Acipimox 250
RxNorm normalized name: acipimox 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox 250 mg orally three times a day for 4-6 weeks
Trial: 10411763
Drug: 0.5 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg.kg‐1 midazolam (n=100)
Trial: 10411763
Drug: 1.0 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg.kg‐1 midazolam (n=100)
Trial: 10411763
Drug: Intranasal ethyl
RxNorm normalized name: Ethyl Acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal ethyl chloride spray
Trial: 10411763
Drug: 0.5 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg.kg‐1 midazolam
Trial: 10411763
Drug: 1.0 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg.kg‐1 midazolam
Trial: 2160379
Drug: Trimethoprim-polymyxin B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-polymyxin B sulphate cream (0.17 mg/g trimethoprim and 10,000 IU/g polymyxin B sulphate)
Trial: 2160379
Drug: Fusidic acid
RxNorm normalized name: Fusidic acid
DrugBank: Fusidic acid (DB02703)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fusidic acid cream (20 mg/g)
Trial: 6107292
Drug: No capsule
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No capsule
Trial: 25369277
Drug: CoQ10 (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoQ10 (600 mg) daily for 11 days
Trial: 11226791
Drug: Cefotaxime 0.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime 0.25% (0.4 mL)
Trial: 11226791
Drug: Balanced Salt
RxNorm normalized name: Balanced Salt Solution
DrugBank: Magnesium chloride (DB09407)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Balanced Salt Solution (BSS) (control)
Trial: 8029191
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg folic acid 3 times per week
Trial: 8029191
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg folic acid 3 times per week
Trial: 8029191
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg folic acid 3 times per week (Control)
Trial: 4552464
Drug: Dummy tablets
RxNorm normalized name: cholecalciferol / tricalcium phosphate Chewable Tablet [Caltrate Gummy Bites]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dummy tablets (Control)
Trial: 26179754
Drug: Dulaglutide 0.75
RxNorm normalized name: DULAGLUTIDE 0.75MG/0.5ML INJ PEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dulaglutide 0.75 mg once-weekly
Trial: 15738298
Drug: Topical decongestant
RxNorm normalized name: Qlearquil Nasal Decongestant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical decongestant and external dilator strip
Trial: 15738298
Drug: Placebo and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and sham treatment
Trial: 15321623
Drug: Thromboembolic deterrent
RxNorm normalized name: oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thromboembolic deterrent stockings (TED) and sequential compression device (SCD)
Trial: 2499203
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg praziquantel
Trial: 16084181
Drug: Access to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Access to drug samples
Trial: 16084181
Drug: No access
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No access to drug samples
Trial: 3176837
Drug: Buprenorphine (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (0.6 mg in 20 ml NaCl)
Trial: 3176837
Drug: Naloxone (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (0.4 mg in 20 ml NaCl)
Trial: 31743542
Drug: 1% BOI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% BOI lotion (ceramide HS) applied once a day for 6 months
Trial: 19579946
Drug: Daily iron
RxNorm normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily iron supplementation (15 drops)
Trial: 19579946
Drug: Weekly iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly iron supplementation (30 drops)
Trial: 19579946
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of daily vs weekly iron supplementation
Trial: 14982566
Drug: Dextromethorphan (270
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextromethorphan (270 mg)
Trial: 11338024
Drug: Cytoreductive surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoreductive surgery (pleuropneumonectomy) followed by sequential chemotherapy and radiotherapy
Trial: 11338024
Drug: Single-modality therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-modality therapy (surgery, radiotherapy, chemotherapy)
Trial: 8170529
Drug: quazepam (15-30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: quazepam (15-30 mg, median 15 mg)
Trial: 8170529
Drug: triazolam (0.25-0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: triazolam (0.25-0.5 mg, median 0.25 mg)
Trial: 18776000
Drug: Cardiac resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac resynchronization therapy alone (COMPANION)
Trial: 18776000
Drug: Cardiac resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac resynchronization therapy plus implantable cardioverter defibrillator (COMPANION)
Trial: 18776000
Drug: Cardiac resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac resynchronization therapy alone (CARE-HF)
Trial: 17161052
Drug: Noninvasive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noninvasive treatment strategy
Trial: 10805207
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate (BDP) via pressurized metered-dose inhaler (MDI)
Trial: 27009822
Drug: Oral NTHi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral NTHi vaccine (HI-164OV)
Trial: 24769011
Drug: Insulin-dependent diabetes
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-dependent diabetes group
Trial: 15741989
Drug: L-carnitine 1
RxNorm normalized name: L-Carnitine 1,000mg Oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine 1 g orally three times a day for 12 weeks
Trial: 9800081
Drug: Vestibular rehabilitation
RxNorm normalized name: Recombinant Vesicular Stomatitis Virus (rVSV) strain Indiana with a deletion of the VSV envelope glycoprotein (G) replaced with the Zaire Ebola Virus (ZEBOV) Kikwit 1995 strain surface glycoprotein (GP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vestibular rehabilitation therapy
Trial: 361463
Drug: Mazindol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mazindol (2 mg/day for 12 weeks)
Trial: 28619061
Drug: Rituximab 1
RxNorm normalized name: rituximab 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab 1 g intravenously, twice at an interval of 2 weeks
Trial: 28619061
Drug: Cyclophosphamide 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide 600 mg/m2 body surface area intravenously, given monthly
Trial: 26341455
Drug: Early feeding
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early feeding (fasting for 4 hours after endoscopic therapy)
Trial: 26341455
Drug: Delayed feeding
RxNorm normalized name: SET,FEEDING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed feeding (fasting for 48 hours after endoscopic therapy)
Trial: 20427425
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of a megadose of cholecalciferol (10,000 IU kg(‐1), max 600,000 IU)
Trial: 20427425
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of a megadose of cholecalciferol
Trial: 18777031
Drug: AS100 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS100 vaccine
Trial: 16919747
Drug: Levomethadyl acetate
RxNorm normalized name: Levomethadyl acetate
DrugBank: Levacetylmethadol (DB01227)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levomethadyl acetate (LAAM), 255-391 mg
Trial: 16919747
Drug: Buprenorphine (BUP),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (BUP), 56-112 mg
Trial: 16919747
Drug: Methadone (METH),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone (METH), 420-700 mg
Trial: 9105981
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups received 5 mg of epidural morphine after intubation
Trial: 8478661
Drug: IL-2/IFN (IL-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-2/IFN (IL-2 0.8 mg/m2 and IFN 3 x 10(6) U/m2)
Trial: 8478661
Drug: IL-2 alone
RxNorm normalized name: Ile
DrugBank: Isoleucine (DB00167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IL-2 alone (1.33 mg/m2)
Trial: 2429335
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg piroxicam each morning
Trial: 2429335
Drug: Therapeutic exercise
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic exercise (conservative treatment)
Trial: 25692797
Drug: Financial incentives
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Financial incentives for medication adherence
Trial: 22978687
Drug: TSH >30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TSH >30 μU/mL after 4 weeks of thyroid hormone withdrawal (THW)
Trial: 22978687
Drug: TSH >80-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TSH >80-100 μU/mL after 4 weeks of THW
Trial: 22978687
Drug: TSH >20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TSH >20 μU/mL with Tg <0.2 ng/mL
Trial: 16816226
Drug: Family focused
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family focused grief therapy (53 families, 233 individuals)
Trial: 9219391
Drug: Fluoxetine as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine as an adjunct to treatment for cocaine abuse
Trial: 3591689
Drug: Dobutamine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobutamine therapy at incremental doses of 2.5, 5, 7.5, 10, 12.5 and 15 micrograms/kg/min
Trial: 3591689
Drug: Milrinone as
RxNorm normalized name: Milrinone
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Milrinone as a bolus of 50 or 75 micrograms/kg followed by an infusion of 0.5 to 1.0 micrograms/kg/min
Trial: 25767373
Drug: Revexepride 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Revexepride 1 mg
Trial: 25767373
Drug: Revexepride 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Revexepride 1 mg + Omeprazole 40 mg
Trial: 9282236
Drug: Turbuhaler (TH)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Turbuhaler (TH) with 0.5 mg terbutaline
Trial: 9282236
Drug: pressurized metered-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pressurized metered-dose inhaler (pMDI) with 0.5 mg terbutaline
Trial: 9282236
Drug: pressurized metered-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pressurized metered-dose inhaler (pMDI)
Trial: 8334346
Drug: Sheng Mai
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sheng Mai injection
Trial: 3113147
Drug: Naloxone administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone administration (8 mg iv as a bolus followed by an infusion of 4 mg/h for 4 h)
Trial: 3113147
Drug: Testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate (200 mg im every two weeks)
Trial: 22032285
Drug: Oxygen therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen therapy (2 L/min through nasal prongs)
Trial: 22032285
Drug: Oxygen therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen therapy and ASV
Trial: 21170109
Drug: S-Gel 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-Gel 5.0 g
Trial: 21170109
Drug: S-Gel 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-Gel 7.5 g
Trial: 17971716
Drug: CD4 cell
RxNorm normalized name: lisocabtagene maraleucel
DrugBank: Lisocabtagene maraleucel (DB16582)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD4 cell count-guided episodic antiretroviral therapy
Trial: 21596364
Drug: Ezetimibe (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe (10 mg) added to stable rosuvastatin 5 mg or 10 mg
Trial: 21596364
Drug: Ezetimibe plus
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe plus rosuvastatin 5 mg
Trial: 21596364
Drug: Ezetimibe plus
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe plus rosuvastatin 10 mg
Trial: 21596364
Drug: Ezetimibe (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe (10 mg) added to stable rosuvastatin
Trial: 21596364
Drug: Rosuvastatin up-titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin up-titration
Trial: 16275885
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg sildenafil twice daily for 4 weeks
Trial: 11865971
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg Cenestin (Synthetic Conjugated Estrogens, A) tablets, administered once daily for 90 days
Trial: 2505269
Drug: BCG (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG (150 mg)
Trial: 2505269
Drug: ADM (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADM (50 mg)
Trial: 2505269
Drug: TTPA (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TTPA (50 mg)
Trial: 11514481
Drug: Statin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin treatment for secondary prevention of coronary heart disease (CHD)
Trial: 11514481
Drug: Statin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin treatment for primary prevention at CHD risk 30% over 10 years
Trial: 11514481
Drug: Statin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin treatment for primary prevention at CHD risk 20% over 10 years